MK-2206 + lapatinib

MK-2206 + lapatinib is an investigational combination therapy consisting of two oral small molecule inhibitors. MK-2206 is an allosteric inhibitor of AKT (protein kinase B), a key component in the PI3K/AKT signaling pathway involved in cell survival and proliferation. Lapatinib is a dual tyrosine kinase inhibitor targeting both human epidermal growth factor receptor 2 (HER2/ERBB2) and epidermal growth factor receptor (EGFR/ERBB1). The rationale for combining these agents is to overcome resistance to HER2-targeted therapies by simultaneously inhibiting upstream HER-family signaling and downstream AKT-mediated survival pathways. This combination has been studied primarily in advanced solid tumors, especially HER2-positive breast cancer, where preclinical data suggest synergistic antitumor activity. Clinical trials have demonstrated that the combination can be tolerated at doses above biologically active single-agent levels, with overlapping toxicities such as diarrhea and rash that are generally manageable[1][2][4]. The primary developer of MK-2206 is Merck & Co., while lapatinib was developed by GSK.

Brand names

TykerbTyverb

Other names

lapatinib ditosylateAKT inhibitor MK-2206 + lapatinib